五氨基水杨酸：老药再评价的新进展。
Five-aminosalicylic Acid: an update for the reappraisal of an old drug.
机构信息
Unit of Clinical Pharmacology, National Research Council-Institute of Neuroscience, Department of Biomedical and Clinical Sciences "Luigi Sacco", University Hospital "Luigi Sacco", Università di Milano, 20157 Milan, Italy.
Unit of General Surgery, Department of Biomedical and Clinical Sciences "Luigi Sacco", University Hospital "Luigi Sacco", Università di Milano, 20157 Milan, Italy.
出版信息
Gastroenterol Res Pract. 2015;2015:456895. doi: 10.1155/2015/456895. Epub 2015 Jan 21.
Inflammatory bowel disease (IBD) comprises several conditions with chronic or recurring immune response and inflammation of the gastrointestinal apparatus, of which ulcerative colitis and Crohn's disease are the commonest forms. This disease has a significant prevalence and it is of an unknown aethiology. Five-aminosalicylic acid (5-ASA) and its derivatives are among the oldest drugs approved for the treatment of the IBD. In this review we reapprise aspects of 5-ASA mechanism of action, safety, and efficacy that in our opinion make it a valuable drug that can be fruitfully tailored in personalised treatments as a therapeutic option alongside other immune-modifying agents.
炎症性肠病（IBD）包括几种具有慢性或复发性免疫反应和胃肠道炎症的疾病，其中溃疡性结肠炎和克罗恩病是最常见的形式。这种疾病的患病率很高，其病因尚不清楚。5-氨基水杨酸（5-ASA）及其衍生物是最早被批准用于治疗 IBD 的药物之一。在这篇综述中，我们重新评估了 5-ASA 的作用机制、安全性和疗效，我们认为它是一种有价值的药物，可以与其他免疫调节剂一起作为治疗选择，为个体化治疗提供更多的选择。
Zotero 插件